Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical. "I don't date people who don't take care ...
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...
Paul Hinds, a cybersecurity expert who likes yoga and bicycling, was diagnosed with prostate cancer about five years ago. He tried multiple treatments before turning to intramuscular shots of Lupron ...
A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...
DEAR DR. ROACH: Approximately five years ago, I was diagnosed with an aggressive prostate cancer. My urologist referred me for radiation therapy, to be followed by Lupron every six months for two ...
Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron.
"Advanced prostate cancer can have a devastating impact on patients and their quality of life," says Dr. Andrew Loblaw, Clinician Scientist and Head of Genitourinary Radiation Oncology Clinical ...
Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical. "I don't date people who don't take care ...
AbbVie announced that a new 6-month 45mg Lupron Depot (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback